2026-08-11 Microdose (industry)

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Research

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On August 5, 2026, the Cambridge, Massachusetts-based biotech (NASDAQ: ENVB) released new preclinical data it says strengthens the argument that its lead candidate, EB-003, can do exactly that. The post Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High appeared first on Microdose.

External link. We are not responsible for the content.

Read more ↗

More From Microdose (industry)

2026-08-11 Microdose (industry)

Psychedelic Medicine Is Having an Identity Crisis — And That’s a Good Thing

For most of the last decade, the story of psychedelic medicine was a story about the trip itself. Guided sessions. Ey...

2026-07-28 Microdose (industry)

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies develo...

Research
2026-07-13 Microdose (industry)

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psy...

Latest News

2026-08-11 Psychedelics Today

Weekly Psychedelic Policy Briefing – August 9, 2026

Jack Gorsline, investigative journalist, covers four federal developments this week. The Department of Veterans Affai...

2026-08-10 MAPS

MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA

August 10, 2026 — The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today responded to an A...

2026-08-10 The Microdose (Berkeley)

Why don’t some people respond to psychedelics? 5 Questions for psychologist Rachel Ham

Ham discusses doing interviews with clinical trial participants who didn’t experience substantial benefits.

2026-08-10 Psychedelics Today

Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?

MAPS co-executive director Ismail Lourido Ali on what the April 2026 executive order, the Texas and Colorado funding ...

2026-08-10 DoubleBlind Magazine

Could Ayahuasca Help Minimize the Loneliness Epidemic?

PLUS, ketamine clinics in Beirut, the Horizons conference, and trip-free psychedelics. [...] Read More... The post Co...

2026-08-09 Breaking Convention (Substack)

Nikki Wyrd - A Tribute

Dear Breakero,